Index
RUT
Market Cap
201.92M
Enterprise Value
129.83M
Income
-113.50M
Sales
3.84M
Book/sh
8.29
Cash/sh
7.97
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
58
IPO
Oct 03, 2019
P/E
-
Forward P/E
-
PEG
-
P/S
52.58
P/B
1.69
P/C
1.76
P/FCF
-
EV/EBITDA
-
EV/Sales
33.81
Quick Ratio
8.13
Current Ratio
8.13
Debt/Eq
0.36
LT Debt/Eq
0.34
Option/Short
Yes / Yes
EPS (ttm)
-11.68
EPS next Y
-5.39
EPS next Q
-1.34
EPS this Y
56.56%
EPS next Y
0.59%
EPS next 5Y
25.06%
EPS past 3/5Y
62.00% 21.21%
Sales past 3/5Y
- -29.61%
EPS Y/Y TTM
-23.75%
Sales Y/Y TTM
-20.31%
EPS Q/Q
32.11%
Sales Q/Q
-100.00%
Insider Own
31.33%
Insider Trans
57.98%
Inst Own
59.00%
Inst Trans
28.75%
ROA
-58.83%
ROE
-87.78%
ROIC
-71.06%
Gross Margin
10.75%
Oper. Margin
-2154.03%
Profit Margin
-2954.14%
SMA20
15.32%
SMA50
15.23%
SMA200
-17.01%
Trades
Shs Outstand
14.42M
Shs Float
10.08M
52W High
55.89 -74.95%
52W Low
5.20 169.00%
Volatility
8.03% 9.86%
ATR (14)
1.16
RSI (14)
60.73
Beta
3.02
Rel Volume
1.85
Avg Volume
175.22K
Volume
324,589
Perf Week
15.04%
Perf Month
27.27%
Perf Quarter
10.67%
Perf Half Y
77.22%
Perf YTD
74.78%
Perf Year
6.95%
Perf 3Y
-19.08%
Perf 5Y
-96.90%
Perf 10Y
-
Prev Close
13.65
Price
14.00
Change
2.56%
Date
Action
Analyst
Rating Change
Price Target Change
May-18-26 Initiated Citigroup
Buy
$21
Mar-13-26 Upgrade Raymond James
Mkt Perform → Outperform
$23
Feb-17-26 Upgrade William Blair
Mkt Perform → Outperform
Jan-29-26 Upgrade Piper Sandler
Neutral → Overweight
$30
Jan-29-26 Upgrade H.C. Wainwright
Neutral → Buy
$20
Jan-29-26 Upgrade Chardan Capital Markets
Neutral → Buy
$15
Jan-28-26 Upgrade Oppenheimer
Perform → Outperform
$22
Jan-28-26 Upgrade Cantor Fitzgerald
Neutral → Overweight
$21
Nov-13-25 Downgrade William Blair
Outperform → Mkt Perform
Nov-13-25 Downgrade RBC Capital Mkts
Outperform → Sector Perform
$8
Nov-13-25 Downgrade Raymond James
Strong Buy → Mkt Perform
Nov-13-25 Downgrade Piper Sandler
Overweight → Neutral
$11
Nov-13-25 Downgrade H.C. Wainwright
Buy → Neutral
Nov-13-25 Downgrade Chardan Capital Markets
Buy → Neutral
$7
Nov-13-25 Downgrade Cantor Fitzgerald
Overweight → Neutral
Apr-29-25 Initiated Cantor Fitzgerald
Overweight
$74
Apr-16-25 Initiated Chardan Capital Markets
Buy
$25
Jan-10-25 Initiated Oppenheimer
Outperform
$155
Oct-21-24 Initiated Raymond James
Strong Buy
$153
Aug-14-24 Initiated William Blair
Outperform
$180
Show Previous Ratings
May-27-26 07:00AM
May-19-26 07:00AM
May-15-26 04:05PM
May-07-26 07:00AM
May-05-26 04:05PM
07:30AM
Loading…
Apr-16-26 07:30AM
Apr-10-26 04:05PM
Mar-12-26 04:05PM
Mar-10-26 06:09AM
Mar-09-26 07:30AM
Feb-26-26 12:15PM
Feb-25-26 04:05PM
Feb-02-26 09:53AM
Jan-30-26 07:35AM
03:08AM
09:35AM
Loading…
Jan-29-26 09:35AM
Jan-20-26 08:00AM
Jan-08-26 08:00AM
Nov-13-25 09:45AM
09:37AM
(Investor's Business Daily)
Nov-12-25 05:59PM
05:40PM
04:05PM
Sep-02-25 04:30PM
Aug-12-25 07:00AM
Jul-21-25 08:00AM
May-14-25 04:05PM
May-09-25 10:31AM
May-07-25 04:30PM
(GlobeNewswire)
-5.85%
+10.55%
Apr-01-25 07:30AM
07:30AM
Loading…
07:30AM
Mar-28-25 06:18PM
Mar-18-25 07:00AM
Mar-17-25 07:26AM
(Pharmaceutical Business Review)
Mar-14-25 08:00AM
Feb-26-25 08:00AM
Jan-13-25 08:00AM
Jan-07-25 08:00AM
Dec-10-24 08:00AM
Nov-21-24 04:01PM
07:30AM
Nov-14-24 08:00AM
Nov-12-24 04:05PM
(GlobeNewswire)
-11.37%
-15.55%
Nov-04-24 07:25AM
Oct-21-24 04:15PM
(Investor's Business Daily)
-5.22%
-7.70%
Oct-16-24 04:20PM
(Investor's Business Daily)
+93.66%
Sep-30-24 08:00AM
Sep-16-24 08:00AM
Sep-10-24 08:00AM
Aug-28-24 08:00AM
Aug-27-24 08:00AM
Aug-13-24 04:01PM
Jul-01-24 08:00AM
Jun-25-24 12:53PM
May-30-24 04:01PM
May-20-24 02:30PM
May-14-24 10:55PM
04:01PM
Apr-18-24 08:30AM
Apr-01-24 04:01PM
Mar-26-24 04:01PM
Feb-27-24 09:55AM
08:00AM
Feb-09-24 09:55AM
Jan-18-24 08:00AM
Jan-04-24 08:00AM
Dec-07-23 08:00AM
Nov-28-23 08:00AM
Nov-03-23 03:31PM
12:19PM
Aug-10-23 04:01PM
Jul-17-23 11:59AM
Jul-14-23 11:22AM
06:30AM
May-12-23 04:01PM
Mar-10-23 07:30AM
Feb-27-23 07:30AM
Feb-13-23 01:55PM
(American City Business Journals)
-80.54%
11:17AM
08:05AM
Dec-19-22 07:30AM
Dec-15-22 07:30AM
Nov-17-22 07:30AM
Nov-08-22 04:05PM
Oct-12-22 07:30AM
Aug-30-22 07:30AM
Aug-09-22 04:05PM
(Business Wire)
-11.11%
+9.00%
Jun-24-22 09:03AM
May-25-22 12:00PM
May-18-22 07:30AM
May-04-22 04:30PM
Apr-22-22 07:30AM
Apr-08-22 05:00PM
Mar-15-22 07:30AM
Mar-10-22 06:35PM
Feb-28-22 07:30AM
Jan-14-22 05:43AM
Jan-04-22 07:30AM
Dec-28-21 02:38AM
Dec-09-21 01:18PM
Korro Bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of a new class of genetic medicines based on editing RNA. The company was founded by Nessan Bermingham, Jean-Francois B. Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.
Ph.D. Dr. Ram Aiyar MBA
MBA Dr. Jean-Francois Formela M.D.
Chief Scientific Officer Dr. Loic Vincent Ph.D.
Pharm.D. Dr. Jeffrey M. Cerio J.D.
Co-Founder & Advisor Dr. Andrew Fraley Ph.D.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Atlas Venture Opportunity Fund Shareholder Jul 02 '26 Proposed Sale 13.65 14,745 201,269 Jul 02 04:41 PM Atlas Venture Fund XI, L.P. Shareholder Jul 02 '26 Proposed Sale 13.65 85,955 1,173,286 Jul 02 04:41 PM FORMELA JEAN FRANCOIS Director Jun 23 '26 Sale 14.25 119,005 1,695,821 176,649 Jun 24 08:09 PM FORMELA JEAN FRANCOIS Director Jun 24 '26 Sale 14.61 48,438 707,491 169,556 Jun 24 08:09 PM FORMELA JEAN FRANCOIS Director Jun 22 '26 Sale 13.95 3,962 55,270 194,075 Jun 24 08:09 PM Atlas Venture Fund XI, L.P. Shareholder Jun 24 '26 Proposed Sale 13.71 41,345 566,840 Jun 24 05:50 PM Atlas Venture Opportunity Fund Shareholder Jun 24 '26 Proposed Sale 13.71 7,093 97,245 Jun 24 05:50 PM Atlas Venture Opportunity Fund Shareholder Jun 23 '26 Proposed Sale 13.90 17,426 242,221 Jun 23 06:12 PM Atlas Venture Fund XI, L.P. Shareholder Jun 23 '26 Proposed Sale 13.90 101,579 1,411,948 Jun 23 06:12 PM Atlas Venture Fund XI, L.P. Shareholder Jun 22 '26 Proposed Sale 12.99 21,339 277,194 Jun 22 05:32 PM Atlas Venture Opportunity Fund Shareholder Jun 22 '26 Proposed Sale 12.99 3,661 47,556 Jun 22 05:30 PM Chappell Todd Chief Operating Officer Jun 16 '26 Sale 10.83 3,168 34,309 16,964 Jun 17 04:14 PM Vincent Loic A Chief Scientific Officer Jun 16 '26 Sale 10.83 3,418 37,017 18,297 Jun 17 04:11 PM Cerio Jeffrey General Counsel Jun 16 '26 Sale 10.83 6,609 71,575 35,293 Jun 17 04:08 PM Dolan Oliver Senior Vice President, Finance Jun 16 '26 Sale 10.83 3,383 36,638 18,099 Jun 17 04:05 PM Vincent Loic A Officer Jun 16 '26 Proposed Sale 10.83 3,418 37,017 Jun 16 04:48 PM Cerio Jeffrey Officer Jun 16 '26 Proposed Sale 10.83 6,609 71,576 Jun 16 04:44 PM Dolan Oliver Officer Jun 16 '26 Proposed Sale 10.83 3,383 36,638 Jun 16 04:44 PM Chappell Todd Officer Jun 16 '26 Proposed Sale 10.83 3,168 34,310 Jun 16 04:42 PM Aiyar Ram President and CEO May 29 '26 Sale 12.98 15,152 196,673 74,848 Jun 02 07:00 AM FORMELA JEAN FRANCOIS Director May 28 '26 Sale 13.95 2,860 39,897 194,655 Jun 01 05:35 PM Aiyar Ram Officer May 29 '26 Proposed Sale 12.98 15,152 196,676 May 29 03:09 PM Lynx1 Capital Management LP 10% Owner Mar 31 '26 Buy 10.60 520 5,512 1,538,296 Apr 02 12:00 PM Yang Rick 10% Owner Mar 10 '26 Buy 11.11 207,100 2,300,881 1,297,893 Mar 12 08:15 PM SANDELL SCOTT D 10% Owner Mar 10 '26 Buy 11.11 207,100 2,300,881 1,297,893 Mar 12 08:15 PM New Enterprise Associates 17, 10% Owner Mar 10 '26 Buy 11.11 207,100 2,300,881 1,297,893 Mar 12 08:15 PM Chang Carmen 10% Owner Mar 10 '26 Buy 11.11 207,100 2,300,881 1,297,893 Mar 12 08:15 PM BASKETT FOREST 10% Owner Mar 10 '26 Buy 11.11 207,100 2,300,881 1,297,893 Mar 12 08:15 PM Mathers Edward T 10% Owner Mar 10 '26 Buy 11.11 207,100 2,300,881 1,297,893 Mar 12 08:15 PM Makhzoumi Mohamad 10% Owner Mar 10 '26 Buy 11.11 207,100 2,300,881 1,297,893 Mar 12 08:15 PM Walker Paul Edward 10% Owner Mar 10 '26 Buy 11.11 207,100 2,300,881 1,297,893 Mar 12 08:15 PM Florence Anthony A. Jr. 10% Owner Mar 10 '26 Buy 11.11 207,100 2,300,881 1,297,893 Mar 12 08:15 PM
